


We claim:

1. A compound of formula (IA-I)



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof wherein

X is CR<sup>1</sup> or N;

D is monocyclic aryl or monocyclic heteroaryl; wherein D is substituted with a group E which is selected from -CONH-O-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-OR<sup>x</sup>, -CONH-O-[cycloalkyl]-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-OR<sup>x</sup>, and -CONH-O-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-[cycloalkyl]-OR<sup>x</sup>, and further D can optionally be substituted with one or more of R<sup>z</sup>;

L<sub>2</sub> is -(CR<sup>a</sup>R<sup>b</sup>)<sub>n</sub>-;

Cy<sup>2</sup> is substituted or unsubstituted heteroaryl;

each occurrence of R<sup>1</sup> and R<sup>2</sup> is hydrogen;

each occurrence of R<sup>a</sup> and R<sup>b</sup> may be same or different and are independently selected from hydrogen, hydroxy, halogen, and substituted or unsubstituted C<sub>1-6</sub> alkyl,


each occurrence of R<sup>x</sup> and R<sup>y</sup> is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy; wherein

each occurrence of R<sup>z</sup> is independently hydrogen, halogen, or substituted or unsubstituted alkyl;

each occurrence of  $n$  independently represents 0, 1, 2, 3 or 4;

each occurrence of  $p$  independently represents 1, 2, 3, 4, 5, 6, 7 or 8.

2. A compound of claim 1, wherein





E is selected from  $-\text{CONH}-\text{O}-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$ ,  $-\text{CONH}-\text{O}-(\text{cycloalkyl})-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$ , and  $-\text{CONH}-\text{O}-(\text{CR}^x\text{R}^y)_p-(\text{cycloalkyl})-\text{OR}^x$ , and

$\text{X}^1$ ,  $\text{X}^2$  and  $\text{X}^3$  are independently selected from  $-\text{CR}^z$ ,  $-\text{CR}^z=\text{CR}^z$ ,  $-\text{CR}^z=\text{N}$ ,  $-\text{N}=\text{CR}^z$ ,  $-\text{N}=\text{N}-$ ,  $\text{O}-$ ,  $-\text{S}-$  or  $-\text{N}-$ ; wherein each occurrence of  $\text{R}^z$  is independently hydrogen, halogen, or substituted or unsubstituted alkyl.


3. A compound of any one of claims 1 and 2, wherein  $\text{Cy}^2$  is unsubstituted heteroaryl.

4. A compound of any one of claims 1-2, wherein  $\text{Cy}^2$  is selected from





5. A compound of claim 4, wherein  $Cy^2$  is selected from




6. A compound of any one of claims 1-5, wherein  $L_2$  is  $-CR^aR^b-$ .

7. A compound of claim 6, wherein  $L_2$  is  $-CH_2-$ ,  $-CH(OH)-$ ,  $-CHF-$ ,  $-CF_2-$ ,  $-CH(CH_3)-$  or  $-C(CH_3)_2-$ .


8. A compound of any one of claims 1-7, wherein  $L_2$  is  $-CH_2-$ .

9. A compound of formula (IA-I):



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof, wherein



$-L^1-Cy^2$  is  
bond to the bicyclic core in formula (IA-I);

each occurrence of  $R^a$  and  $R^b$  are independently selected from hydrogen, halogen, and substituted or unsubstituted ( $C_{1-6}$ ) alkyl;

$Z$  is selected from  $CR^c$ , S, O,  $NR^c$ ,  $R^cC=CR^c$ ,  $-N=CR^c$ -, and  $-R^cC=N$ -;

$Z_1$  is selected from N,  $NR^c$  and  $CR^c$ ;

$Z_2$  and  $Z_3$  are independently selected from C or N;

$R^c$  is absent or selected from hydrogen, hydroxy and halogen;

$X$  is  $CR^1$  or N;

$D$  is monocyclic aryl or monocyclic heteroaryl; wherein  $D$  is substituted with a group  $E$  which is selected from  $-CONH-O-(CR^xR^y)_p-OR^x$ ,  $-CONH-O-[cycloalkyl]-(CR^xR^y)_p-OR^x$ , and  $-CONH-O-(CR^xR^y)_p-[cycloalkyl]-OR^x$ , and further  $D$  can optionally be substituted with one or more of  $R^2$ ;


each occurrence of  $R^1$  and  $R^2$  is hydrogen;

each occurrence of  $R^x$  and  $R^y$  is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;

each occurrence of  $R^z$  is independently hydrogen, halogen, or substituted or unsubstituted alkyl, and



each occurrence of  $p$  independently represents 1, 2, 3, 4, 5, 6, 7 or 8.

10. A compound of formula (IA-I):



(IA-I)

or a tautomer, stereoisomer, enantiomer, diastereomer, a prodrug, a pharmaceutically acceptable salt, or N-oxide thereof, wherein



(where the squiggly line represents the bond to

the bicyclic core in formula (IA-I);

X is CR<sup>1</sup> or N;

X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> are independently selected from -CR<sup>2</sup>, -CR<sup>2</sup>=CR<sup>2</sup>, -CR<sup>2</sup>=N, -N=CR<sup>2</sup>, -N=N-, O-, -S- or -N-;

Z is selected from CR<sup>c</sup>, S, O, NR<sup>c</sup>, R<sup>c</sup>C=CR<sup>c</sup>, -N=CR<sup>c</sup>-, and -R<sup>c</sup>C=N-;

Z<sub>1</sub> is selected from N, NR<sup>c</sup> and CR<sup>c</sup>;

Z<sub>2</sub> and Z<sub>3</sub> are independently selected from C or N;

E is selected from  $-\text{CONH}-\text{O}-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$ ,  $-\text{CONH}-\text{O}-[\text{cycloalkyl}](\text{CR}^x\text{R}^y)_p-\text{OR}^x$ , and  $-\text{CONH}-\text{O}-(\text{CR}^x\text{R}^y)_p-[\text{cycloalkyl}]-\text{OR}^x$ , and further D can optionally be substituted with one or more of  $\text{R}^z$ ;

each occurrence of  $\text{R}^1$  and  $\text{R}^2$  is hydrogen;

each occurrence of  $\text{R}^a$  and  $\text{R}^b$  may be same or different and are independently selected from hydrogen, halogen, and substituted or unsubstituted  $\text{C}_{1-6}$  alkyl;

each occurrence of  $\text{R}^x$  and  $\text{R}^y$  is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;

each occurrence of  $\text{R}^z$  is independently hydrogen, halogen, or substituted or unsubstituted alkyl;


each occurrence of q independently represents 0, 1 or 2;


each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8.


11. A compound of claim 2 or claim 10, wherein  $\text{X}^1$  and  $\text{X}^2$  are  $\text{CR}^z$  and  $\text{X}^3$  is independently selected from  $-\text{CR}^z=\text{CR}^z$  and  $-\text{S}-$ .

12. A compound of claim 11, wherein  $\text{X}^1$  is  $\text{CH}$ ,  $\text{X}^2$  is  $\text{CR}^z$  and  $\text{X}^3$  is  $-\text{CR}^z=\text{CR}^z$ , wherein  $\text{R}^z$  is hydrogen, halogen or substituted or unsubstituted  $\text{C}_{1-6}$  alkyl.


13. A compound of any one of claims 1-12, wherein D is selected from









14. A compound of claim 13, wherein D is selected from




15. A compound of any one of claims 1-12, wherein D is selected from



16. A compound of claim 15, wherein E is selected from



17. A compound of claim 15 or claim 16, wherein E is selected from



18. A compound of claim 15, wherein each occurrence of  $R^Z$  is selected from hydrogen, halogen or substituted or unsubstituted alkyl.
19. A compound of claim 18, wherein each occurrence of  $R^Z$  is selected from hydrogen, fluoro, chloro, methyl or  $CF_3$ .
20. A compound of claims 9-19, wherein each of  $R^a$  and  $R^b$  is hydrogen, alkyl or halogen.
21. A compound of any one of claims 9-20, wherein
- both  $R^a$  and  $R^b$  are hydrogen;
  - $R^a$  is methyl and  $R^b$  is hydrogen;
  - $R^a$  is fluoro and  $R^b$  is hydrogen;
  - $R^a$  and  $R^b$  both are fluoro; or
  - $R^a$  and  $R^b$  both are methyl.
22. A compound of any one of claims 9-21, wherein
- Z is  $CR^c$ , N, S, O,  $HC=CH-$  or  $-N=CH-$ ;
- $Z_1$  is CH or N;
- $Z_2$  is C; and
- $Z_3$  is C or N.

23. A compound of any one of claims 9-22, wherein

- a) Z is -HC=CH-, -S- or -O-; Z<sub>1</sub> is CH; Z<sub>2</sub> is C and Z<sub>3</sub> is C or N;
- b) Z is -HC=CH-, Z<sub>1</sub> is CH; Z<sub>2</sub> is C; and Z<sub>3</sub> is C;
- c) Z is CH, Z<sub>1</sub> is CH, Z<sub>2</sub> is C and Z<sub>3</sub> is N;
- d) Z is -S-, Z<sub>1</sub> is CH, Z<sub>2</sub> is C and Z<sub>3</sub> is C;
- e) Z is -O-, Z<sub>1</sub> is CH, Z<sub>2</sub> is C and Z<sub>3</sub> is C; or
- f) Z is -CH-, Z<sub>1</sub> is NH, Z<sub>2</sub> is C and Z<sub>3</sub> is C.

24. A compound of any one of claims 9-23, wherein each occurrence of R<sup>c</sup> is hydrogen or fluoro.

25. A compound of any one of claims 1-24, wherein X is N or CR<sup>1</sup> and R<sup>1</sup> is H, substituted or unsubstituted C<sub>1-6</sub> alkyl, NH<sub>2</sub>, OH, CN or CONH<sub>2</sub>.

26. A compound of any one of claims 1-25, wherein X is N.

27. A compound of any one of claims 1-26, wherein each R<sup>2</sup> is H.

28. A compound selected from:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide hydrochloride:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

sodium (2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

sodium (2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

sodium (2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride

sodium (2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-fluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-(tert-butoxycarbonylamino)propanoate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-aminopropanoate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pyalate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-benzamidoacetate:

2-chloro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-chloro-N-(2-hydroxyethoxy)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluoro-N-(2-hydroxyethoxy)benzamide:

sodium (4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluorobenzoyl)(2-hydroxyethoxy)amide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-fluoro-N-(2-hydroxyethoxy)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate:

N-(2-hydroxyethoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

6-((5-(4-(2-hydroxyethoxycarbonyl)-3-methylphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide hydrochloride:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

ethyl 2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)acetate:

2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl benzoate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl furan-2-carboxylate:

and pharmaceutically acceptable salts thereof.

29. A compound selected from:

N-(2-Hydroxy-ethoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-ethoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide:

or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition comprising a compound of any one of claims 1-29 and a pharmaceutically acceptable carrier.

31. The pharmaceutical composition of claim 30, further comprising one or more additional therapeutic agents and mixtures thereof.

32. The pharmaceutical composition of claim 31, wherein the one or more additional therapeutic agent is an anti-cancer agent, anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or a mixture thereof.

33. A compound of any one of claims 1-29 for use in inhibiting the HGF/c-Met kinase signaling pathway in a cell.

34. A compound of any one of claims 1-29 for use in inhibiting the proliferative activity of a cell.

35. A compound of any one of claims 1-29 for use in inhibiting tumor growth.

36. A compound of any one of claims 1-29 for use in inhibiting tumor metastasis.

37. A compound of any one of claims 1-29 for use in the treatment of a c-Met associated disease or disorder.


38. A compound of any one of claims 1-29 for use in the treatment of cancer.

39. The compound of claim 38, wherein said cancer is a carcinoma, musculoskeletal sarcoma, soft tissue sarcoma, or hematopoietic malignancy.

40. The compound of claim 39, wherein said cancer is carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma; cholangiocarcinoma cancer, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma; tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannoma; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, multiple myeloma, lymphoma, glioblastoma, astrocytoma, melanoma, mesothelioma, Wilm's tumor, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia.

## CLAIMS

1. A compound of formula (IA-I)



(IA-I)

or a stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof; wherein

X is CR<sup>1</sup> or N;

D is monocyclic aryl or monocyclic heteroaryl; wherein D is substituted with a group E which is selected from -CONH-O-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-OR<sup>x</sup>, -CONH-O-[cycloalkyl]-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-OR<sup>x</sup>, and -CONH-O-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-[cycloalkyl]-OR<sup>x</sup>, and further D can optionally be substituted with one or more of R<sup>z</sup>;

L<sub>2</sub> is -(CR<sup>a</sup>R<sup>b</sup>)<sub>n</sub>-;

Cy<sup>2</sup> is substituted or unsubstituted heteroaryl;

each occurrence of R<sup>1</sup> and R<sup>2</sup> is hydrogen;

each occurrence of R<sup>a</sup> and R<sup>b</sup> may be same or different and are independently selected from hydrogen, hydroxy, halogen, and substituted or unsubstituted C<sub>1-6</sub> alkyl,


each occurrence of R<sup>x</sup> and R<sup>y</sup> is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy; wherein

each occurrence of R<sup>z</sup> is independently hydrogen, halogen, or substituted or unsubstituted alkyl;

each occurrence of  $n$  independently represents 0, 1, 2, 3 or 4;

each occurrence of  $p$  independently represents 1, 2, 3, 4, 5, 6, 7 or 8.

2. A compound of claim 1, wherein





E is selected from  $-\text{CONH-O}-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$ ,  $-\text{CONH-O}[\text{cycloalkyl}](\text{CR}^x\text{R}^y)_p-\text{OR}^x$ , and  $-\text{CONH-O}-(\text{CR}^x\text{R}^y)_p-[\text{cycloalkyl}]-\text{OR}^x$ , and

$\text{X}^1$ ,  $\text{X}^2$  and  $\text{X}^3$  are independently selected from  $-\text{CR}^z$ ,  $-\text{CR}^z=\text{CR}^z$ ,  $-\text{CR}^z=\text{N}$ ,  $-\text{N}=\text{CR}^z$ ,  $-\text{N}=\text{N}-$ , O-, -S- or -N-; wherein each occurrence of  $\text{R}^z$  is independently hydrogen, halogen, or substituted or unsubstituted alkyl.



3. A compound of any one of claims 1 and 2, wherein  $\text{Cy}^2$  is unsubstituted heteroaryl.

4. A compound of any one of claims 1-2, wherein  $\text{Cy}^2$  is selected from






5. A compound of claim 4, wherein  $Cy^2$  is selected from




6. A compound of any one of claims 1-5, wherein  $L_2$  is  $-CR^aR^b-$ .
7. A compound of claim 6, wherein  $L_2$  is  $-\text{CH}_2-$ ,  $-\text{CH}(\text{OH})-$ ,  $-\text{CHF}-$ ,  $-\text{CF}_2-$ ,  $-\text{CH}(\text{CH}_3)-$  or  $-\text{C}(\text{CH}_3)_2-$ .
8. A compound of any one of claims 1-7, wherein  $L_2$  is  $-\text{CH}_2-$ .
9. A compound of formula (IA-I):



(IA-I)

or a stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof, wherein



$-L_2-Cy^2$  is

(where the squiggly line represents the bond to the bicyclic core in formula (IA-I);

each occurrence of  $R^a$  and  $R^b$  are independently selected from hydrogen, halogen, and substituted or unsubstituted ( $C_{1-6}$ ) alkyl;

$Z$  is selected from  $CR^c$ , S, O,  $NR^c$ ,  $R^cC=CR^c$ ,  $-N=CR^c-$ , and  $-R^cC=N-$ ;

$Z_1$  is selected from N,  $NR^c$  and  $CR^c$ ;

$Z_2$  and  $Z_3$  are independently selected from C or N;

$R^c$  is absent or selected from hydrogen, hydroxy and halogen;

$X$  is  $CR^1$  or N;

$D$  is monocyclic aryl or monocyclic heteroaryl; wherein  $D$  is substituted with a group  $E$  which is selected from  $-CONH-O-(CR^xR^y)_p-OR^x$ ,  $-CONH-O-[cycloalkyl]-(CR^xR^y)_p-OR^x$ , and  $-CONH-O-(CR^xR^y)_p-[cycloalkyl]-OR^x$ , and further  $D$  can optionally be substituted with one or more of  $R^z$ ;


each occurrence of  $R^1$  and  $R^2$  is hydrogen;

each occurrence of  $R^x$  and  $R^y$  is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;

each occurrence of  $R^z$  is independently hydrogen, halogen, or substituted or unsubstituted alkyl, and



each occurrence of  $p$  independently represents 1, 2, 3, 4, 5, 6, 7 or 8.

10. A compound of formula (IA-I):



(IA-I)

or a stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof, wherein



X is CR<sup>1</sup> or N;

X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> are independently selected from -CR<sup>z</sup>, -CR<sup>z</sup>=CR<sup>z</sup>, -CR<sup>z</sup>=N, -N=CR<sup>z</sup>, -N=N-, O-, -S- or -N-;

Z is selected from CR<sup>c</sup>, S, O, NR<sup>c</sup>, R<sup>c</sup>C=CR<sup>c</sup>, -N=CR<sup>c</sup>, and -R<sup>c</sup>C=N-;

Z<sub>1</sub> is selected from N, NR<sup>c</sup> and CR<sup>c</sup>;

Z<sub>2</sub> and Z<sub>3</sub> are independently selected from C or N;

E is selected from -CONH-O-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-OR<sup>x</sup>, -CONH-O-[cycloalkyl]-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-OR<sup>x</sup>, and -CONH-O-(CR<sup>x</sup>R<sup>y</sup>)<sub>p</sub>-[cycloalkyl]-OR<sup>x</sup>, and further D can optionally be substituted with one or more of R<sup>z</sup>;

each occurrence of  $R^1$  and  $R^2$  is hydrogen;

each occurrence of  $R^a$  and  $R^b$  may be same or different and are independently selected from hydrogen, halogen, and substituted or unsubstituted  $C_{1-6}$  alkyl;

each occurrence of  $R^x$  and  $R^y$  is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;

each occurrence of  $R^z$  is independently hydrogen, halogen, or substituted or unsubstituted alkyl;


each occurrence of  $q$  independently represents 0, 1 or 2;

each occurrence of  $p$  independently represents 1, 2, 3, 4, 5, 6, 7 or 8.


11. A compound of claim 2 or claim 10, wherein  $X^1$  and  $X^2$  are  $CR^z$  and  $X^3$  is independently selected from  $-CR^z=CR^z$  and  $-S-$ .

12. A compound of claim 11, wherein  $X^1$  is  $CH$ ,  $X^2$  is  $CR^z$  and  $X^3$  is  $-CR^z=CR^z$ , wherein  $R^z$  is hydrogen, halogen or substituted or unsubstituted  $C_{1-3}$  alkyl.


13. A compound of any one of claims 1-12, wherein  $D$  is selected from









14. A compound of claim 13, wherein D is selected from




15. A compound of any one of claims 1-12, wherein D is selected from



16. A compound of claim 15, wherein E is selected from



17. A compound of claim 15 or claim 16, wherein E is selected from



18. A compound of claim 15, wherein each occurrence of  $R^Z$  is selected from hydrogen, halogen or substituted or unsubstituted alkyl.

19. A compound of claim 18, wherein each occurrence of  $R^Z$  is selected from hydrogen, fluoro, chloro, methyl or  $CF_3$ .

20. A compound of claims 9-19, wherein each of  $R^a$  and  $R^b$  is hydrogen, alkyl or halogen.

21. A compound of any one of claims 9-20, wherein

- a) both  $R^a$  and  $R^b$  are hydrogen;

- b)  $R^a$  is methyl and  $R^b$  is hydrogen;
- c)  $R^a$  is fluoro and  $R^b$  is hydrogen;
- d)  $R^a$  and  $R^b$  both are fluoro; or
- e)  $R^a$  and  $R^b$  both are methyl.

22. A compound of any one of claims 9-21, wherein

$Z$  is  $CR^c$ , N, S, O,  $HC=CH-$  or  $-N=CH-$ ;

$Z_1$  is CH or N;

$Z_2$  is C; and

$Z_3$  is C or N.

23. A compound of any one of claims 9-22, wherein

- a)  $Z$  is  $-HC=CH-$ ,  $-S-$  or  $-O-$ ;  $Z_1$  is CH;  $Z_2$  is C and  $Z_3$  is C or N;
- b)  $Z$  is  $-HC=CH-$ ,  $Z_1$  is CH;  $Z_2$  is C; and  $Z_3$  is C;
- c)  $Z$  is CH,  $Z_1$  is CH,  $Z_2$  is C and  $Z_3$  is N;
- d)  $Z$  is  $-S-$ ,  $Z_1$  is CH,  $Z_2$  is C and  $Z_3$  is C;
- e)  $Z$  is  $-O-$ ,  $Z_1$  is CH,  $Z_2$  is C and  $Z_3$  is C; or
- f)  $Z$  is  $-CH-$ ,  $Z_1$  is NH,  $Z_2$  is C and  $Z_3$  is C.

24. A compound of any one of claims 9-23, wherein each occurrence of  $R^c$  is hydrogen or fluoro.

25. A compound of any one of claims 1-24, wherein X is N or  $CR^1$  and  $R^1$  is H, substituted or unsubstituted  $C_{1-6}$  alkyl,  $NH_2$ , OH, CN or  $CONH_2$ .

26. A compound of any one of claims 1-25, wherein X is N.

27. A compound of any one of claims 1-26, wherein each  $R^2$  is H.

28. A compound selected from:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide hydrochloride:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

sodium (2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

sodium (2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

sodium (2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride

sodium (2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-fluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-(tert-butoxycarbonylamino)propanoate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-aminopropanoate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-benzamidoacetate:

2-chloro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-chloro-N-(2-hydroxyethoxy)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluoro-N-(2-hydroxyethoxy)benzamide:

sodium (4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluorobenzoyl)(2-hydroxyethoxy)amide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-fluoro-N-(2-hydroxyethoxy)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate:

N-(2-hydroxyethoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

6-((5-(4-(2-hydroxyethoxycarbonyl)-3-methylphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide hydrochloride:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

ethyl 2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidooxy)acetate:

2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl benzoate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl furan-2-carboxylate:

and pharmaceutically acceptable salts thereof.

29. A compound selected from:

N-(2-Hydroxy-ethoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-ethoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide:

or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition comprising a compound of any one of claims 1-29 and a pharmaceutically acceptable carrier.

31. A compound of any one of claims 1-29 for use in inhibiting the HGF/c-Met kinase signaling pathway in a cell.

32. A compound of any one of claims 1-29 for use in inhibiting the proliferative activity of a cell.

33. A compound of any one of claims 1-29 for use in inhibiting tumor growth.

34. A compound of any one of claims 1-29 for use in inhibiting tumor metastasis.

35. A compound of any one of claims 1-29 for use in the treatment of a c-Met associated disease or disorder.

36. A compound of any one of claims 1-29 for use in the treatment of cancer.

37. The compound of claim 36, wherein said cancer is a carcinoma, musculoskeletal sarcoma, soft tissue sarcoma, or hematopoietic malignancy.

38. The compound of claim 36, wherein said cancer is carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma; cholangiocarcinoma cancer, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma; tumors of the central and peripheral

nervous system, astrocytoma, neuroblastoma, glioma, schwannoma; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, multiple myeloma, lymphoma, glioblastoma, astrocytoma, melanoma, mesothelioma, Wilm's tumor, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia.

39. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for inhibiting the HGF/c-Met kinase signaling pathway in a cell.

40. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for inhibiting the proliferative activity of a cell.

41. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for inhibiting tumor growth.

42. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for inhibiting tumor metastasis.

43. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for the treatment of a c-Met associated disease or disorder.

44. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for the treatment of cancer.

45. The use of claim 44, wherein said cancer is a carcinoma, musculoskeletal sarcoma, soft tissue sarcoma, or hematopoietic malignancy.

46. The use of claim 44, wherein said cancer is carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma; cholangiocarcinoma cancer, tumors of

mesenchymal origin, fibrosarcoma, rhabdomyosarcoma; tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannoma; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderma pigmentosum, keratoanthoma, thyroid follicular cancer and Kaposi's sarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, multiple myeloma, lymphoma, glioblastoma, astrocytoma, melanoma, mesothelioma, Wilm's tumor, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia.